A PYMNTS Company

The FTC vs. The War On Cancer

By  |  September 11, 2022

By Wall Street Journal

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Thank you for the editorial “Antitrust’s Unholy Grail” (Sept. 7) on the fate of Illumina’s acquisition of Grail, the firm behind the miracle of blood tests that can detect early-occurring cancer cells, enabling early treatment for at least 50 types of cancer.

    Previous U.S. presidents announced a war on cancer. President Biden has said much the same. Yet now that Grail has an amazing test, the Federal Trade Commission sees reasons to stop it from getting the help it needs to make its test more widely available. The FTC does…

    Continue Reading…